Two independent advances in lipid nanoparticle design promise to improve mRNA and gene‑therapy delivery by tuning tissue tropism and immune cell metabolism. Researchers described a class of ‘tripod‑like’ lung‑targeting lipids that bias LNP delivery to pulmonary tissues, enhancing lung uptake for inhaled or systemic gene therapies. Separately, a study redesigned ionizable LNP chemistry with imidoester crosslinkers to reprogram dendritic cell metabolism—boosting immune organ targeting and generating stronger vaccine responses while reducing inflammatory side effects in preclinical models. That work demonstrated that LNP composition can actively modulate antigen‑presenting cell metabolism to improve efficacy and tolerability. Together, the findings expand LNP design from passive carriers to active immunomodulators and tissue‑directing platforms, opening paths for targeted gene therapies for lung disease and more potent, better‑tolerated mRNA vaccines. Developers will need to translate these chemistry and targeting advances into scalable formulations and assess safety and biodistribution in larger animal models before clinical testing.